FDA Approves Immunotherapy Drug
The FDA has approved the immunotherapy drug nivolumab (Opdivo) for patients with metastatic colorectal cancer that has one of two specific genetic features, high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). These genetic features are hallmarks of most Lynch Syndrome tumors.
Learn more:
https://www.cancer.gov/news-events/cancer-currents-blog/2017/nivolumab-fda-colorectal